Agile Therapeutics (NASDAQ:AGRX) Earning Somewhat Positive Press Coverage, Analysis Finds

Share on StockTwits

Press coverage about Agile Therapeutics (NASDAQ:AGRX) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agile Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 48.5370935788406 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of research analysts recently issued reports on the company. HC Wainwright set a $8.00 price objective on Agile Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 28th. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. William Blair downgraded Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th. Janney Montgomery Scott downgraded Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, December 22nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $5.00 price target on shares of Agile Therapeutics in a research note on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Agile Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Shares of NASDAQ AGRX opened at $2.76 on Friday. Agile Therapeutics has a 12 month low of $1.93 and a 12 month high of $5.60.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.05. research analysts predict that Agile Therapeutics will post -0.71 earnings per share for the current fiscal year.

WARNING: “Agile Therapeutics (NASDAQ:AGRX) Earning Somewhat Positive Press Coverage, Analysis Finds” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://baseballnewssource.com/2018/04/06/agile-therapeutics-agrx-receives-media-impact-rating-of-0-23/2030524.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Insider Buying and Selling by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.